Literature DB >> 9625933

The scourge of HIV-related tuberculosis: a cohort study in a district general hospital in Malawi.

A D Harries1, D S Nyangulu, C Kangombe, D Ndalama, J J Wirima, F M Salaniponi, G Liomba, D Maher, P Nunn.   

Abstract

Malawi is similar to a number of other African countries in having an escalating, HIV-related, tuberculosis (TB) epidemic. A prospective study was carried out to determine the pattern of disease and HIV serostatus in unselected, adult, TB patients consecutively admitted to a large, district general hospital in Zomba (in the Southern region of Malawi). Clinical details were obtained, from the district TB register, for the 714, adult TB patients, aged > or = 15 years, who were registered with the district TB officer between 1 July and 31 December in 1995. Patients were counselled, and offered HIV testing using an ELISA and particle agglutination test. Concordant HIV-test results were available for 686 (96%) of the subjects: 547 (80%) of these were HIV-seropositive and 139 seronegative. The HIV-positive patients were significantly younger than the HIV-negative patients and significantly more HIV-positive patients were males (P < 0.05 for each). The proportions of HIV-positive subjects who were new patients, had been previously treated for TB, had pulmonary TB (PTB), had smear-positive PTB or had different types of extrapulmonary TB were similar to those of the HIV-negative. A high percentage of an unselected cohort of adult TB patients admitted to a district, general hospital in Malawi, particularly of the younger age groups was therefore HIV-positive. The pattern of disease was uninfluenced by the HIV serostatus. The large number of cases registered emphasises the severity of the current epidemic of TB in Malawi and its impact upon young adults.

Entities:  

Mesh:

Year:  1997        PMID: 9625933     DOI: 10.1080/00034989760527

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  8 in total

1.  Prevalence of pulmonary tuberculosis (PTB) among people living with HIV/AIDS (PLWHA) in Keffi and its environs.

Authors:  Grace R Pennap; Joseph N Giyan; Angela T Eleboda
Journal:  Indian J Microbiol       Date:  2009-06-13       Impact factor: 2.461

2.  Epidemiology of Tuberculosis in Malawi.

Authors:  Thomas Nyirenda
Journal:  Malawi Med J       Date:  2006-09       Impact factor: 0.875

3.  Epidemiology of HIV/AIDS in adults in Malawi.

Authors:  Eveline Geubbels; Cameron Bowie
Journal:  Malawi Med J       Date:  2006-09       Impact factor: 0.875

4.  Impact of human immunodeficiency virus and CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South Africa.

Authors:  R K Gupta; S D Lawn; L-G Bekker; J Caldwell; R Kaplan; R Wood
Journal:  Int J Tuberc Lung Dis       Date:  2013-08       Impact factor: 2.373

5.  Elevated HIV seroprevalence and risk behavior among Ugandan TB suspects: implications for HIV testing and prevention.

Authors:  P Srikantiah; R Lin; M Walusimbi; A Okwera; H Luzze; C C Whalen; W H Boom; D V Havlir; E D Charlebois
Journal:  Int J Tuberc Lung Dis       Date:  2007-02       Impact factor: 2.373

6.  Mycobacterial antigens in pleural fluid mononuclear cells to diagnose pleural tuberculosis in HIV co-infected patients.

Authors:  Tehmina Mustafa; Ida Wergeland; Kamaldeen Baba; Sharad Pathak; Anwar A Hoosen; Anne Margarita Dyrhol-Riise
Journal:  BMC Infect Dis       Date:  2020-07-01       Impact factor: 3.090

7.  IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting.

Authors:  Ida Marie Hoel; Melissa Davidsen Jørstad; Msafiri Marijani; Morten Ruhwald; Tehmina Mustafa; Anne Ma Dyrhol-Riise
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

8.  Characteristics of Patients with Smear-Negative Pulmonary Tuberculosis (TB) in a Region with High TB and HIV Prevalence.

Authors:  Leandro Cruz Campos; Marcos Vinícius Vieira Rocha; Denise Maria Cunha Willers; Denise Rossato Silva
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.